WSJ
27 Oct 2026, 06:36 UTC · 2h ago
Impact · against what's priced in
Novartis sees a modest net positive catalyst as raised guidance outweighs short-term clinical setbacks. The guidance increase suggests stronger-than-expected sales and productivity, while the Q3 profit hit is likely viewed as a transitory event.
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
What the story claims
2 claims · scored −1 bearish … +1 bullish · 2 new · 0 priced in
Novartis has raised its financial guidance based on solid sales growth and productivity gains.
Newpublished 2026-10-27
So whatUpward revisions typically lead to an increase in analysts' FY2026 EPS estimates.
More positive than 93% of claims this week
Clinical-trial setbacks negatively impacted Novartis's bottom line in the third quarter.
Continue reading
5 related stories
Newpublished 2026-10-27
So whatThese one-time hits to Q3 profit may mask underlying margin expansion from productivity gains.
More negative than 87% of claims this week
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Reuters
1h ago
